Quick Asked: Zafgen Contact Us?
Last update: 01 May, 2024 
293 Views
Listing Results Zafgen Contact Us? Question Answers
FDA hits Zafgen’s beloranib successor with clinical hold
The FDA has placed a clinical hold on Zafgen’s ZGN-1061. Zafgen suffered the blow after failing to allay the FDA’s concerns that ZGN ...
Jobs with Zafgen
126 articles with Zafgen. Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics. 5/29/2020 - Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused ...
Experts in Residence (XIRs) Harvard Office of Technology
Find the advice you need. Venture capitalists, executives and legal experts are just a phone call away. Our network of Experts in Residence (XIRs) offers a powerful resource for Harvard innovators working to commercialize a technology, navigating the launch of a startup, or seeking corporate partners.. Our XIRs have a wealth of experience in: company formation and ...
FDA puts Zafgen's diabetes trial on hold Reuters
Zafgen Inc said on Monday the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of its experimental diabetes drug, citing possible heart safety risks.
Working At Zafgen Zippia
Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity. The company s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled
Zafgen Nature Biotechnology
Zafgen was founded in 2005 to exploit Folkman's TNP-470 findings, but anti-angiogenesis turned out to be a red herring for obesity. When James Vath, Zafgen's first employee and now head of
Jeff Hatfield's email & phone Vividion Therapeutics's
Chief Executive Officer @ Vividion Therapeutics; Board Member @ Vir Biotechnology, Inc. Chief Executive Officer @ Zafgen, Inc. see more Member of the Board of Advisors @ Harvard Business School Chair of the Board of Directors @ Miragen Therapeutics, Inc. Board Director, Chair Nominations and Governance @ Atyr Pharma Board Member, Executive Committee Member ...
Zafgen hangs 'for sale' sign as chances of imminent
Zafgen has enlisted MTS Health Partners to help with its hunt for strategic alternatives. Shares in Zafgen fell 14% following the news, bringing their value down to around $0.70 a pop. Back in
EIN 203857670 Zafgen, Inc., Boston, Massachusetts
Organization Profile. Zafgen, Inc. is a corporation in Boston, Massachusetts. The employer identification number (EIN) for Zafgen, Inc. is 203857670. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K filings with the SEC.
Zafgen, Inc. Glancy Prongay & Murray LLP
On October 16, 2015, Zafgen disclosed that it received verbal notice from the U.S. Food and Drug Administration that the clinical trials involving beloranib, a drug designed to reduce hunger while stimulating the use of stored fat as an energy source, have been placed on partial hold following the death of a patient enrolled in a beloranib trial.
Zafgen Animal Health, LLC in Wilmington, DE Company Info
Zafgen Animal Health, LLC is a Delaware Limited-Liability Company filed On October 15, 2010. The company's File Number is listed as 4885640. The Registered Agent on file for this company is The Corporation Trust Company and is located at Corporation Trust Center 1209 Orange St, Wilmington, DE 19801.
Zafgen Announces Agreement with U.S. Food and Drug
Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Media/Investor Relations Contacts: Zafgen, Inc.
Zafgen Securities Corporation in Boston, MA Company Info
Zafgen Securities Corporation is a Massachusetts Domestic Profit Corporation filed On December 19, 2008. The company's File Number is listed as 000992046. The Registered Agent on file for this company is Thomas Hughes and is located at 1 Broadway 8th Flr., Cambridge, MA 02142.
Zafgen, Inc. Relationship Science
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders.
Zafgen Inc Hours hoursfinder.com
Zafgen Company Profile - Office Locations, Competitors https://craft.co/zafgen. May 29, 2020 · BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced ...
Kerrisdale Capital Zafgen, Inc. (ZFGN) Kerrisdale Capital
Zafgen is a biopharmaceutical company on the brink of extinction. From its founding in 2005, Zafgen’s “big idea,” in the words of one piece of early press coverage, was to “fight fat by cutting off its blood supply.” After licensing a drug called beloranib that was originally designed to inhibit angiogenesis (the development of new blood vessels) in order to treat cancer, Zafgen
Larimar Therapeutics Crunchbase Company Profile & ...
844-511-9056 Legal Name Zafgen, Inc. Stock Symbol NASDAQ:LRMR Company Type For Profit Contact Email [email protected] Phone Number 844-511-9056 Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Zafgen Inc. Company Profile San Diego, CA ...
(443) 213-0506 Address: 9191 Towne Centre Dr Ste L103 San Diego, CA, 92122-6204 United States Phone: (443) 213-0506 Website: www.larimartx.com
Zafgen and Chondrial Therapeutics Announce Definitive
617-648-9792 Zafgen, Inc. Patricia Allen Chief Financial Officer 617-648-9792 Media Krystle Gibbs Ten Bridge Communications [email protected] 508-479-6358 Investors John Woolford Westwicke [email protected] ...
Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar Therapeutics also plans
Zafgen EquityNet
Zafgen is the world's first biopharmaceutical company dedicated to developing novel obesity therapeutics that directly target and shrink fat tissue to help the body regain and sustain a lean, healthy state. Adipose tissue (fat) is composed primarily of cells that store unused calories for later use. The balance between how the body stores excess calories and later accesses these ...
Zafgen Donates Hyperphagia Questionnaire to FPWR for Use
Zafgen, Inc., has donated its Hyperphagia Questionnaire for Clinical Trials (HQ-CT) instrument to FPWR to help enable the development of potential therapies for Prader-Willi syndrome.. The HQ-CT is derived from a well-established, caregiver-reported questionnaire initially developed by Dr. Elisabeth Dykens and her team at Vanderbilt University that provides an assessment of the ...
Contact Us Larimar Therapeutics, Inc. zafgen.gcsweb.com
© 2021 Larimar Therapeutics, Inc. All rights reserved. LARIMAR and LARIMAR THERAPEUTICS are trademarks of Larimar Therapeutics, Inc.
Zafgen Suspends PraderWilli Syndrome Treatment, CMO
More bad news keeps coming for Massachusetts-based Zafgen. Shares of Zafgen are down more than 22 percent in premarket trading after the company announced Monday that it was suspending plans to develop a treatment for Prader-Willi syndrome (PWS).. During its year-end financial report on Monday, Zafgen said it has suspended plans to file an ...
{{item.primary.intro}} {{item.primary.title}}
212.326.2251 CONTACT: Andrea Rodeschini. O’Melveny & Myers LLP. 212.326.2251. [email protected] . SILICON VALLEY, CA - DECEMBER 4, 2012 - O’Melveny & Myers LLP represented Alta Partners, a leading venture capital firm in life sciences, as lead investor in Zafgen, Inc.’s US$21 million Series D equity financing. Zafgen, Inc. is a biopharmaceutical
LogicBio Therapeutics , Inc. Information LogicBio
Scouring the web at all hours of the night wasn't gonna cut it. RocketReach has given us a great place to start. Our workflow has solid direction now - we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering.
Didn't get an answer?
Recent Posts
- Home ›
- Z ›
- Zafgen Contact Us?